Expanding trial data demands new analytical methods

Published: 29-Oct-2016
Media Regulatory Digital

With research methods and new technologies focused on acquiring individual information from clinical trial participants, the qualitative and quantitative volume of collectable data is growing at an accelerating rate

You need to be a subscriber to read this article.
Click here to find out more.

Effectively managing trial data is challenging and drug sponsors are increasingly compelled to leverage new analytical methods, technologies and partnerships to get the most value from massive sets of unique trial data.

As a result of improving smart mobile technologies and the growing popularity of wearable devices, clinical trial managers are now capable of gathering and analysing more data than ever before. More significantly, new technology and analytical methods are helping to improve both the volume and the quality of trial data while increasing patient involvement and convenience in the process.

Streamlining the complexities associated with effective trial data management is challenging, even for the most adept research-based organisations. According to The 2016 Nice Insight CRO Outsourcing Survey, 76% of respondents outsourced clinical trial services and 50% outsourced clinical trial data management (Figure 1).1

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • Thats Nice
See more

You may also like

Media

Slow and steady

Read more
Generic drugs find a growing position in the US pharma market

Trending Articles

  1. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey
  2. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services
  5. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Media

Slow and steady

Generic drugs find a growing position in the US pharma market
You need to be a subscriber to read this article.
Click here to find out more.
Media

CRISPR in clinical trials: the future of gene editing

Gene editing is a technology that allows scientists to alter an organism’s genomic DNA, reports Emilie Branch, Strategic Content Manager, That’s Nice
You need to be a subscriber to read this article.
Click here to find out more.
Media

The growth of immuno-oncology: active, passive and hybrid treatments into 2020

Immuno-oncology is poised to become the fourth pillar in cancer treatment, which currently includes chemotherapy, radiation therapy and surgery
You need to be a subscriber to read this article.
Click here to find out more.
Media

The contract development and manufacturing pulse is steady and strong

Pharma’s CDMOs are sticking to strategic 'fitness' programmes to increase capacity and operational muscle, and compete for elusive market share
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Latest developments in cellular and gene therapies

Although numerous cellular and gene therapy products are currently in different phases of clinical trials, only 14 have been approved for use by FDA to date
You need to be a subscriber to read this article.
Click here to find out more.
Media

Move toward cell-based manufacturing signals opening in vaccine market

Global investments and initiatives by governmental and non-governmental organisations are bringing considerable growth to the vaccines and vaccination market
You need to be a subscriber to read this article.
Click here to find out more.
Media

Can epi-drugs capture the next wave of growth?

An explosion in the field of epigenetics has revealed multiple ‘goldmines’ in the form of biological targets. Pharmaceutical companies with the most developed implementation capabilities are likely to capture the next wave of this growth
Subscribe now